Suzanne Johnson - Pfizer Independent Director
| PFE Stock | EUR 25.70 0.07 0.27% |
Director
Ms. Suzanne M. Nora Johnson, J.D., is an Independent Director of Pfizer Inc., since September 27, 2007. She is Retired Vice Chairman, Goldman Sachs Group, Inc., since 2007. During her 21year tenure with Goldman Sachs, served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Director of American International Group, Inc., Intuit Inc. and Visa Inc. Vice Chair, Board of Trustees of The Brookings Institution CoChair of the Board of Trustees of the Carnegie Institution of Washington CoChair of the Board of Trustees of the University of Southern California and member of the Global Agenda Council on the Future of Financial and Monetary Systems for the World Economic Forum. Ms. Nora Johnsons careers in law and investment banking, including serving in various leadership roles at Goldman Sachs, provide valuable business experience and critical insights into the roles of the law and finance when evaluating strategic transactions. Ms. Nora Johnson also brings financial expertise to the Board, providing an understanding of financial statements, corporate finance, accounting and capital markets since 2007.
| Age | 62 |
| Tenure | 18 years |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
| Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
| Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Lead Independent Director | ||
| Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
| Susan DesmondHellmann, Director | ||
| Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
| Gordon Loh, Senior Vice President Corporate Audit | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
| Susan Hockfield, Independent Director | ||
| Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
| Dan Littman, Independent Director | ||
| James Kilts, Independent Director | ||
| James Quincey, Independent Director | ||
| Joseph Echevarria, Independent Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Angela Hwang, Group President, Pfizer Biopharmaceuticals Group | ||
| Scott Gottlieb, Independent Director | ||
| Ronald Blaylock, Independent Director |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 276.06 B | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 2.90 X | |||
| Revenue | 100.33 B | |||
| EBITDA | 39.58 B | |||
| Net Income | 31.37 B | |||
| Total Debt | 34.76 B | |||
| Cash Flow From Operations | 32.58 B | |||
| Price To Earnings To Growth | 1.17 X | |||
| Number Of Employees | 39 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Pfizer Stock
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.